Characteristics | Nr. |
All | 18 |
Median age (years, range) | 53 (32–75) |
Median BMI (Kg/m2, range) | 24 (17–35) |
Tumor entities | |
Cervix | 9 (50.0%) |
Corpus uteri | 7 (38.9%) |
Ovary | 2 (11.1%) |
Type of tumor | |
Primary | 8 (44.4%) |
Recurrent | 10 (55.6%) |
Tumor size (mm) | 46 (30–80) |
Pretreatment | |
None | 2 (11.1%) |
Chemotherapy | 4 (22.2%) |
Surgery | 3 (16.7%) |
Chemo-radiotherapy | 3 (16.7%) |
Chemotherapy + surgery | 4 (22.2%) |
Surgery + radiotherapy | 1 (5.6%) |
Chemo- radiotherapy + surgery | 1 (5.6%) |
Median operating time (min, range) | 415 (285–615) |
Intra-operative median blood loss (ml, range) | 285 (100–600) |
Median number of blood transfusions (range) | 0 (0–2) |
Intra-operative ureteral stenting | |
Unilateral | 8 (44.4%) |
Bilateral | 10 (56.6%) |
Intra-operative complications * | 3 (16.7%) |
Median abdominal drainage removal (days, range) | 6 (1–21) |
Median vesical catheter removal (days, range) | 15 (1–40) |
Median length of hospital stays (days, range) | 10 (4–22) |
Median major post-operative complications † | 6 (33.3%) |
Adjuvant treatment | |
None | 6 (33.3%) |
Chemotherapy | 10 (55.6%) |
Radiotherapy | 1 (5.6%) |
Chemotherapy and radiotherapy | 1 (5.6%) |
*one vesical injury, one ureteral injury, and one vascular injury.
†upper to G1 according to Franco-Italian glossary.